Stryker Sells U.S. Spinal Implants Business

Stryker to Sell its U.S. Spinal Implants Business
“We believe that the spinal implants business, with its comprehensive portfolio and strong sales channel, will thrive as an independent company," said Kevin A. Lobo, Chair and Chief Executive Officer, Stryker. "With dedicated resources and a focused strategy, the business will be well positioned to succeed as part of Viscogliosi Brothers.”
Stryker to sell spine business: 8 notes for ASCs
Here are eight things for ASCs to know about the sale: 1. Stryker's U.S. spine segment will be sold to investment firm Viscogliosi Brothers. 2. That group will create VB Spine, which will be a strategic partner to Stryker with exclusive access to the company's Mako Spine and Copilot technology.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
Stryker Corporation SYK recently announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space,
Stryker to sell spinal implants business
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter. Stryker’s spinal implants business brought in $707 million in sales in 2024, and Lobo clarified that the “entire $700 million is expected to be divested to [VB Spine].”
Stryker to Sell Spinal Implants Business to Viscogliosi Brothers
Stryker has agreed to sell its U.S. spinal implants business to Viscogliosi Brothers to create a newly formed company called VB Spine. The medical technology company said Tuesday the New York City-based Viscogliosi Brothers specializes in neuro-musculoskeletal treatments.
Stryker beats Q4 estimates, sells spinal implants biz
Stryker Corp reported fourth-quarter earnings that beat Wall Street estimates, with earnings of $4.01 per share, ahead of analysts’ expectations of $3.87. Revenue rose to $6.4 billion, slightly ahead of the consensus estimate of $6.
Hosted on MSN8h
Stryker price target raised to $427 from $384 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Stryker (SYK) to $427 from $384 and keeps a Neutral rating on the shares ...
Stryker Corp. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a three-day winning streak.
bovnews18h
Stock Shock: The Unpredictable Rise and Fall of SYK—What’s Driving the Drama?
On Tuesday, Stryker Corp (SYK) stock saw a decline, ending the day at $395.15 which represents a decrease of $-4.75 or -1.19% from the prior close of $399.9. The stock opened at $400.61 and touched a ...
Buy Rating for Stryker: Robust Performance and Strategic Growth Drivers
Analyst Patrick Wood from Morgan Stanley maintained a Buy rating on Stryker (SYK – Research Report) and keeping the price target at ...
Becker's Spine Review14h
Stryker's shoulder robot earns FDA approval
Stryker's Mako shoulder robot earned FDA approval in December, Jason Beach, vice president of finance and investor relations, said in a Jan. 28 earnings call.
WYFF 4 Greenville-Spartanburg on MSN12h
New details released as search continues for missing South Carolina father, two young sons
Detectives in Anderson County, South Carolina, continue to search for a father and his sons after they were reported missing ...
Stryker reports 2024 operating results and 2025 outlook
Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024: Fourth Quarter Results Full Year Results “We delivered another year of double-digit organic sales growth ...
Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Stryker Corporation's innovation and market leadership justify a premium. See why SYK stock is a solid hold with long-term ...